SWEET-PLUS - Supporting adherence to CDK4/6 inhibitors in early breast
Research type
Research Study
Full title
SWEET-PLUS - Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer
IRAS ID
346275
Contact name
Linda Sharp
Contact email
Sponsor organisation
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
CDK4/6 are proteins found in our cells that tell the cell when it is time to grow and get ready to divide. In certain types of breast cancer, the CDK4/6 proteins can tell the cells to divide even when it should not. This is one of the reasons why cancer cells can multiply so fast.
CDK4/6 inhibitors are a type of “targeted” cancer therapy that slows downs or stops cancer cells from dividing. When cancer cells cannot divide as easily, it makes it difficult for them to grow quickly. CDK4/6 inhibitors can come in the form of medicines such as Abemaciclib (brand name Verzenio) or Ribociclib (brand name Kisqali). They are now given to some women with early breast cancer, after their breast cancer surgery; they help lower the chances of the cancer coming back again.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
25/EE/0220
Date of REC Opinion
20 Oct 2025
REC opinion
Further Information Favourable Opinion